Details

Autor(en) / Beteiligte

• Tu, Hua
• Sun, Peng
• Gu, Haifeng
• Zhang, Xinke
• Huang, He
• Wan, Ting
• Liu, Jihong

Titel

Clinical Significance and Prognostic Value of Femoral Lymph Node Metastasis in FIGO Stage III Vulvar Carcinoma

Ist Teil von

• European journal of surgical oncology, 2017-09, Vol.43 (9), p.1768-1775

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• Abstract Objectives To determine the clinical significance and prognostic value of femoral lymph node metastasis (FLNM) in patients with International Federation of Gynecology and Obstetrics (FIGO) stage III vulvar carcinoma. Methods The medical records of patients with vulvar carcinoma who underwent inguinofemoral lymphadenectomy between 1990 and 2013 were retrospectively reviewed. Results Of 66 patients with stage III vulvar carcinoma, 42 had superficial lymph node metastasis (SLNM) only and 24 had FLNM. Significantly higher rates of extracapsular invasion (P=0.008), multiple nodal metastasis (P=0.042), and advanced FIGO substage (P=0.026) as well as a larger tumor diameter (≥4 cm, P=0.023) and greater depth of invasion (≥5 mm, P=0.020) were observed among patients with FLNM compared to those with SLNM only. After a median follow-up of 46 months (range, 6–172 months), 35 patients experienced relapse and 30 died from disease. The 5-year cancer-specific survival (CSS) rates were 70.1% and 30.8% for patients with SLNM only and FLNM, respectively (P=0.001). In multivariate analysis, only FLNM was found to be an independent risk factor for reduced recurrence-free survival (RFS) and CSS among patients with stage III vulvar cancer (hazard ratio [HR]=2.277, P=0.037 for RFS; HR=2.360, P=0.042 for CSS). When the FLNM cases were considered together as stage IIIC, significant differences emerged in the RFS (P=0.002) and CSS (P=0.004) among the re-divided FIGO substages. Conclusions FLNM represented an unfavorable status of node metastasis with a worse prognosis compared to that of SLNM alone, and this should be considered in a future FIGO staging system for vulvar cancer.